Korro Bio Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Korro Bio Inc
Access all reports
Korro Bio Inc. is a biopharmaceutical company engaged in the field of RNA editing to develop new genetic medicines. The company's innovative approach, leveraging the Oligonucleotide Promoted Editing of RNA (OPERA) platform, aims to harness natural processes for making transient, reversible changes to genetic instructions. This technology seeks to offer potential treatments for patients with rare and highly prevalent diseases by overcoming the complexities of earlier gene-editing methods. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.
Key slides for Korro Bio Inc
TD Cowen 45th Annual Healthcare Conference
Korro Bio Inc
Corporate Presentation
Korro Bio Inc
Latest articles
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
Ticker symbol
KRRO
Country
🇺🇸 United States